CN1340344A - Prescription of 'strong heart first-aid dropping pill' and its preparing process - Google Patents
Prescription of 'strong heart first-aid dropping pill' and its preparing process Download PDFInfo
- Publication number
- CN1340344A CN1340344A CN00111303A CN00111303A CN1340344A CN 1340344 A CN1340344 A CN 1340344A CN 00111303 A CN00111303 A CN 00111303A CN 00111303 A CN00111303 A CN 00111303A CN 1340344 A CN1340344 A CN 1340344A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- aid
- water
- dropping pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 8
- 230000008569 process Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 82
- 230000000694 effects Effects 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 17
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 235000005412 red sage Nutrition 0.000 claims abstract description 12
- 230000004927 fusion Effects 0.000 claims abstract description 8
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 13
- 229960001661 ursodiol Drugs 0.000 claims description 13
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 claims description 10
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 claims description 10
- 229930182494 ginsenoside Natural products 0.000 claims description 10
- 229940089161 ginsenoside Drugs 0.000 claims description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 229920002545 silicone oil Polymers 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000003177 cardiotonic effect Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 239000002826 coolant Substances 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 241000208340 Araliaceae Species 0.000 abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 5
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 5
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- KBKUJJFDSHBPPA-UHFFFAOYSA-N 5beta-hydroxylcinobufagin Natural products CC(=O)OC1C2OC22C3CCC4(O)CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 KBKUJJFDSHBPPA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 2
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KBKUJJFDSHBPPA-ZNCGZLKOSA-N cinobufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@@]5(O)CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 KBKUJJFDSHBPPA-ZNCGZLKOSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 229930190011 Bufogenin Natural products 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- FMTLOAVOGWSPEF-KJRPADTMSA-N Gamabufogenin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)[C@H](O)C[C@@]32C)C=CC(=O)OC=1 FMTLOAVOGWSPEF-KJRPADTMSA-N 0.000 description 1
- FMTLOAVOGWSPEF-UHFFFAOYSA-N Gamabufotalin Natural products CC12CC(O)C(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 FMTLOAVOGWSPEF-UHFFFAOYSA-N 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 1
- 229950006858 bufogenin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- -1 or fat-soluble Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A strong heart first-aid dropped pill for treating cardiovascular disease is prepared from 7 Chinese medicinal materials including ginseng, red sage root, musk, etc., and natural medicines through extracting active components, separating or artificial synthesis, fusion, high-pressure homogenization, superfine mixing, emulsifying, dissolving in polyethanediol and dropping it in low-temp. cooler (liquid silica oil) and naturally granulating relying on its surface tension. It has high curative effect.
Description
The present invention relates to the prescription and the preparation method of a kind of cardiovascular diseases's of treatment Chinese medicine preparation " strong heart first-aid dropping pill ".Belong to medical biology field.Function with cure mainly: blood circulation promoting and blood stasis dispelling, invigorate vital energy and reinforce the heart, coronary artery dilating, coronary circulation-promoting pain-relieving is used for the treatment of coronary heart disease, angina pectoris, chest distress and palpitation symptoms, myocardial infarction etc.
Cardiovascular disease is the serious disease of harm humans health, and only just there are more than one hundred million patients in China, and mortality rate is far above cancer and AIDS.
Cardiovascular disease mostly is coronary atherosclerosis makes lumen of vessels narrow down, block, thereby causes myocardial ischemia and the heart disease that causes.Chinese medicine thinks that numbness resistance heart arteries and veins such as many, congestion turbid by hypofunction of YANG QI in chest, YIN-cold, expectorant of primary disease forms.According to the disease characteristics, can belong to disease categories such as the thoracic obstruction, pained, precordial pain with cold limbs.
Many and the inward invasion of pathogenic cold of the generation of cardiovascular disease, disorder of emotion, intemperance of taking food, factors such as fatigue are relevant, and particularly aged debility or middle age are overworked under above-mentioned factor affecting easier generation.Its sick position relates to liver, spleen, internal organs such as kidney at the heart.
Chinese medicine has long history aspect curing angiocardiopathy, but because traditional handicraft falls behind, makes product not bring into play effect to greatest extent, obtains due therapeutic effect.Ancients' cloud: " ball person, slow also ", the production of Chinese medicine pill is through one or more fine drug powders and mixed with excipients, the solid preparation that forms through machining.Because the effective ingredient of medical material does not extract, the fineness of medicated powder can not reach the degree of rapid permeability cell membrane again mostly, therefore makes drug effect not to be not fully exerted.
The research of disease treatment medicine is the hot issue of countries in the world always, but fails so far efficiently always, and is quick-acting, long lasting in conjunction with on reach corresponding uniform.For example: first aid quick-acting aspect, Western medicine nitroglycerin effect is remarkable, but does not have therapeutical effect; Aspect long-acting, some medicine powers of Chinese medicine are out of the ordinary, but can not quick-acting first aids.Though domestic have the cardiopathic Chinese patent medicine of a collection of treatment at present, evident in efficacy is actually rare.In recent years, though more domestic colleagues have also done a large amount of research and developments, in the tradition and the combination in modern times, all there is a certain distance.For example: though have also research and develop drops owing on Technology, fail in-depth, be subjected to all multifactor restrictions, can not fully hold the elite of Chinese medicine, though also improve, be difficult to reach ideal boundary.
The object of the present invention is to provide a kind of taking convenience, evident in efficacy, can help meet an urgent need and can cure the disease, the new medicine preparation for the treatment of both the principal and secondary aspects of a disease.
Another object of the present invention provides the advanced unique preparing process of said preparation.
Solution of the present invention is: under the pathogenetic understanding and Therapeutic Principle guidance of motherland's traditional medicine to cardiovascular disease, use for reference the newest fruits and the advanced technology of domestic and international modern pharmacological research, from motherland's medicine treasure-house, filter out blood circulation promoting and blood stasis dispelling, invigorate vital energy and reinforce the heart, coronary artery dilating, the representative Chinese crude drug of coronary circulation-promoting pain-relieving and the elite of natural drug, by behind the theory of Chinese medical science prescription compatibility, it is carried out comprehensive qualitative and quantitative analysis, on this basis, extract, separation or its effective site of synthetic and effective ingredient carry out scientific combination, adopt solid dispersion technology, it is little to produce dosage, quick-acting, drops efficiently.
The characteristics of solid dispersion technology are: adopt fusion method to make medicine be scattered in the physiology inertia with molecularity and in the carrier soluble in water, form disperse system.Drug particle (0.001-0.1um) is also littler than micronized particles (3-4um), thereby has improved surface area greatly, and its bioavailability is much higher than the medicine of general dosage form.After entering the intestines and stomach, water-solubility carrier dissolves rapidly, because particle is little, the solid dispersion dissolution velocity is fast, can be absorbed by cell rapidly to enter blood circulation, thereby reach efficient and quick-acting effects.Particularly contain a large amount of volatilization zest compositions in the effective site, adopt solid dispersion technology more can fully contain, make it bring into play effect to a greater extent.
Medicine of the present invention is made (consumption is a weight portion) by following component:
Ginsenoside 7-15 part water-soluble extract of red sage root 20-45 part
Artificial Moschus 4-10 part artificial Calculus Bovis 12-24 part
Ursodesoxycholic acid 1-8 part bufotalin 1-8 part
The ratio range that Borneolum Syntheticum 12-22 part prepares the formula optimization weight of medicine of the present invention is:
Ginsenoside 5-12 part water-soluble extract of red sage root 30-40 part
Artificial Moschus 5-8 part artificial Calculus Bovis 15-22 part
Ursodesoxycholic acid 2-6 part bufotalin 2-6 part
The optimum weight proportioning of Borneolum Syntheticum 14-20 part medicine of the present invention is:
40 parts of 10 parts of water-soluble extract of red sage root of ginsenoside
20 parts of 6 parts of artificial Calculus Boviss of artificial Moschus
3.3 parts of 3.3 parts of bufotalins of ursodesoxycholic acid
The method that 17.4 parts of Borneolum Syntheticums are made medicine of the present invention with above-mentioned component is:
1. Stem and leaf of Radix Ginseng is extracted its total Saponin, and be dried to powder;
2. Radix Salviae Miltiorrhizae is extracted water soluble ingredient, and be dried to powder;
3. Venenum Bufonis is isolated main cardiotonic glycoside composition bufotalin with silica gel column chromatography from its chloroform extract, and be dried to powder;
4. choose artificial Moschus, artificial Calculus Bovis, ursodesoxycholic acid, Borneolum Syntheticum by pharmacopeia and ministry standard;
5. choose polyethylene glycol 6000 by national standard.
Illustrate:
1. the stem and leaf of Radix Ginseng total saponins that the present invention extracted is 5% of a crude drug Stem and leaf of Radix Ginseng, and spraying into powder is 200 orders.
Wherein: contained panoxadiol 18.37%, the panaxatriol 55.05%, oleanolic acid 6.66%.
2. the main component of water-soluble extract of red sage root of the present invention is protocatechualdehyde, protocatechuic acid, danshensu, vitamin E
Deng, wherein content of Danshensu 2.5%.
3. the present invention isolates the main component bufotalin with cardiotonic with silica gel column chromatography from the chloroform extracted solution of Venenum Bufonis,
Its main component is: bufogenin (2.735%), cinobufacin (3.08%), Toadpoison Medicine (0.793%), Cinobufotalin
(0.641%), bufotalien (0.296%), Gamabufotalin (0.949%), cinobufacin (0.43%) far away, deacetylate
Cinobufotalin (0.899%).
4. artificial Moschus of the present invention is the state-promulgated pharmacopoeia standard, and its main component muscone, content are 2.46-5.4%.
5. artificial Calculus Bovis of the present invention is a ministry standard, and its main component content is: bilirubin 0.70%, and deoxycholic acid 15%,
Cholic acid 12.5%, cholesterol 2% and 5% inorganic salt and the mixture of volume starch.
6. ursodesoxycholic acid of the present invention is an imported product, meets ministry standard.
7. Borneolum Syntheticum of the present invention is the synthetic product that meet the state-promulgated pharmacopoeia standard.
8. polyethylene glycol 6000 of the present invention is pharmacopeia designated country standard substance.
With ginsenoside in the above-mentioned component and water-soluble extract of red sage root is respectively the solvent dissolving with water, artificial Moschus, artificial Calculus Bovis, ursodesoxycholic acid, bufotalin and Borneolum Syntheticum are respectively the solvent dissolving with the dehydrated alcohol, with the medicine after the above-mentioned dissolving, be no more than 1um through high pressure homogenize ultra micro emulsifying to particle diameter respectively then; 1: 9 taking polyethylene glycol 6000 of ratio in medicine and carrier polyethylene glycol 6000 is heated to 85 ℃ of all thawings; By the order of liposoluble constituent behind the first water soluble ingredient, add in the Polyethylene Glycol one by one and go then, treat that a kind of medicine fully stirs fusion after, be sequentially added into another kind again, until all being miscible in together heat preservation for standby use in the fluid reservoir of 85 ℃ of temperature.
In cryostat liquid silicone oil is poured into layering cooling in the glass tubing that highly is not less than 40cm, make the upper strata reduce to 15 ℃, lower floor reduces to 5 ℃; Medicinal liquid in the fluid reservoir is injected water dropper and dripping of vacuum absorption device that different-diameter is housed make tube.Water dropper apart from the silicon oil liquid identity distance from less than 5cm.Adjust the vac sorb switch, in the liquid paraffin, medicine drips slowly and sinks when making drop splash into glass tubing by preset frequency, relies on the tension force of self to be shrunk to ball gradually.After becoming ball, clean surperficial silicone oil, drying at room temperature and finished product.
An important feature of the present invention be with the effective site in Chinese crude drug and the natural drug on the basis of qualitative and quantitative analysis research, adopt advanced Technology with its extraction separation or synthetic.Make effective ingredient be molecularity (particle diameter of medicine in carrier is between 0.001-0.1um) on the one hand, permeation cell film that can be strong rapidly and blood vessel wall enter blood performance drug effect, increase substantially the dissolution rate of medicine, improve bioavailability of medicament; Because the high concentration of effective ingredient can reach required effect with very little dose, the ratio that merges with carrier can be decreased to 1: 9, makes drug absorption quick on the one hand, and drug effect is multiplied.This just makes the technology level of Chinese medicine compound preparation stride into biology field at one stroke.Since extraction, separation and synthetic the effective ingredient in Chinese crude drug and the natural drug; rare animal and ecological environment have not only been protected; and make the effective ingredient of medicine more stable; more accurate; proportioning production that can qualitative, quantitative; make Chinese medicine in line with international standards, help that Chinese medicine is more massive to go to the world.
Be the medicine dissolution rate that shows medicine of the present invention and the effect of blood drug level peak value duration, twice pair of rabbit of the present invention carried out the zoopery of " to myocardial ischemia antagonism due to the pituitrin ".The result is:
1. myocardial contraction promptly raises 4.5% and strengthen gradually behind the intravenous drug, increases by 18% after 15 minutes;
2. the intravenous injection pituitrin is after 15 seconds, and Cor Leporis flesh shrinks promptly to weaken and recovers normal after 13%, 4 minute, and ECG T wave reduces.
3. administration intravenous injection pituitrin once more after 26 minutes, myocardial contraction reduces by 13% after 45 seconds, and blood pressure does not have significant change, and the persistent period is 25 seconds.Inject weak point recovery time relatively for the first time, electrocardiogram does not have significant change, and the myocardial contraction calibration often increases by 25%.
4. administration intravenous injection pituitrin once more after 38 minutes, myocardial contraction do not have and obviously are suppressed phenomenon, and electrocardiogram and blood pressure do not have significant change.
5. above explanation, " strong heart first-aid dropping pill " can obviously strengthen myocardial contraction, has the effect of myocardial ischemia due to the stronger antagonism pituitrin, onset early, duration is long, so have more the first aid function.
Another important feature of the present invention is the Technology by uniqueness, and effective ingredient as much as possible is organically combined, and fully fusion makes medicine of the present invention more meet motherland's traditional medical theory, more adapts to the pathology cause of disease, and therefore, curative effect is better.
The prescription of medicine of the present invention " strong heart first-aid dropping pill " is China's rare Chinese medicine, and core wherein such as Moschus, Calculus Bovis, Venenum Bufonis, Fel Ursi etc. are again animalities, and its effective ingredient mostly is fat-soluble.How both to have made full use of its active component, and do not lost in the old maxim name and pass, made itself and the abundant fusion of carrier again, adapt to the requirement of new technique, new technology, novel form, thereby significantly improve infiltration and assimilation effect, reach function efficient, quick-acting, treating both the principal and secondary aspects of a disease, this is successful key point.From the Western medicine to Chinese medicine, the medicine of every employing drops mostly is a kind of effective ingredient greatly, and decimal adds a kind of activating agent or resuscitative prescription therein again, extremely discretely reaches three kinds, and is very rare.In these drops, a common characteristic is arranged, be exactly the unicity of effective ingredient, or fat-soluble, or water solublity.This is because industrial circle does not find a kind of sophisticated technology to make the effective ingredient of two kinds dissimilar (chemistry constitutes different certainly with reflection) perfectly merge so far as yet and prepares successfully.This limitation is directly restricting more tradition name Chinese medicines on the one hand and is ranking among the novel form that this is representing the Chinese medicine developing direction; Force existing Producer to have to part reluctantly with what one treasures on the one hand, not willingly forgotten to greatest extent tradition the provoking sb. far superior in power or strength of name side, this is just very difficult take into account comprehensively the illness cause of disease, pathogenesis to the ill, broken the balance mechanism of " monarch, minister, help, make ", its result well imagines." strong heart first-aid dropping pill " prescription is China's rare Chinese medicine, it is fat-soluble that the effective ingredient of its core mostly is the animal class, how both to have made full use of its active component, do not lose in the old maxim name and pass, make again its can with water soluble ingredient and the abundant fusion of carrier thereof, adapt to the requirement of new technique, new technology, novel form, thereby significantly improve infiltration and assimilation effect, reach function quick-acting, efficient, treating both the principal and secondary aspects of a disease, this is exactly the difficult problem of pendulum in face of us from the beginning.We have overcome all beyond thought difficulties by up to a hundred scientific researches, have successfully solved this difficult problem finally.Its main method is:
1. single selects specific solvent to dissolve.
2. isothermal high pressure homogenize ultra micro emulsifying.
3. classification is synthetic.
4. watery fusion by different level.
By above-mentioned comprehensive mechanical, physics, chemical Trinitarian processing step, make the affinity of different pharmaceutical strengthen, fully chemical combination is fused together.Under molten condition, the parallel helical form keys of two of each molecule of carrier polyethylene glycol 6000 launch, and medicine then enters in the curling key of carrier and forms molecular dispersoid; Thereby, make that an above-mentioned difficult problem has obtained properly reasonably solving.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1. quick-acting.Sublingual administration, onset time is short, is better than domestic all Chinese medicine like products, is equal to the Western medicine nitroglycerin.
2. efficient.Blood drug level peak value duration is long, increases by 30% than domestic Chinese medicine like product.
3. dosage is little, curative effect is high.Consumption is 1/2～1/3 of a domestic Chinese medicine like product only, and drug effect significantly improves.
4. price is low.Because prescription is rationally, technology advanced person, the production efficiency height descends product cost significantly, and is calculated in comparable terms low by 50% than domestic like product, is 1/10 of Japanese best brand of product " JIUXIN DAN " (15 milligrams every are worth 5 yuan of RMB approximately).
In order to show the therapeutic effect of medicine of the present invention to cardiovascular disease, the present invention is through the clinical observation of 41 routine patient systems, and to select medical history, the state of an illness, age, sex and suitable cardiovascular patient 23 examples of former Therapeutic Method be matched group, carried out the curative effect comparison.
Two groups of angina pectoris symptom curative effects have very dominance difference (P＜0.01) through X 2 test.See Table 1
Table 1: clinical observation angina pectoris symptom curative effect relatively
Two groups of ECG curative effect have the difference (P＜0.01) of highly significant through X 2 test.See Table 2.
Table 2: the clinical observation ECG curative effect relatively
Statistics shows: with medicine of the present invention 46 routine cardiovascular patients are done therapeutic test, that obtains significant curative effect accounts for 51.22%, substantially effectively accounts for 41.46%, and invalid accounts for 7.32%, and total effective rate reaches 92.68%.
Embodiment (1000,30 milligrams every)
Take by weighing raw material by following proportioning:
Ginsenoside's 0.3 gram water-soluble extract of red sage root 1.2 grams
Artificial Moschus 0.18 gram artificial Calculus Bovis 0.6 gram
Ursodesoxycholic acid 0.1 gram bufotalin 0.1 gram
Borneolum Syntheticum 0.52 gram polyethylene glycol 6000 27 grams
The ratio of effective ingredient and carrier is 1: 9.
Preparation method:
With ginsenoside in the said components and water-soluble extract of red sage root is respectively the solvent dissolving with water, artificial Moschus, artificial Calculus Bovis, ursodesoxycholic acid, bufotalin and Borneolum Syntheticum are respectively the solvent dissolving with the dehydrated alcohol, are no more than 1um through high pressure homogenize ultra micro emulsifying to particle diameter respectively then; Taking polyethylene glycol 6000 is heated to 85 ℃ and all melts; Then, with dissolve the emulsive medicine of ultra micro by first water soluble ingredient after the order of liposoluble constituent, add in the Polyethylene Glycol one by one and go, after treating a kind of abundant stirring fusion, be sequentially added into another kind again, until whole mixed meltings together, heat preservation for standby use in the fluid reservoir of 85 ℃ of temperature.
In cryostat liquid silicone oil is poured into layering cooling in the glass tubing that highly is not less than 40cm, make the upper strata reduce to 15 ℃, lower floor reduces to 5 ℃; Medicinal liquid in the fluid reservoir is injected water dropper and dripping of vacuum absorption device that different-diameter is housed make tube.Water dropper apart from the silicon oil liquid identity distance from less than 5cm.Adjust the vac sorb switch, drop is splashed in the liquid paraffin of glass tubing by preset frequency, medicine drips slowly and sinks, and relies on the tension force of self to be shrunk to ball gradually.After becoming ball, clean surperficial silicone oil, drying at room temperature and finished product.
Claims (10)
1. medicine " strong heart first-aid dropping pill " for the treatment of the cardiovascular diseases is characterized in that it is the medicament of being made by the following weight proportion raw material:
20～45 parts of 7～15 parts of water-soluble extract of red sage root of ginsenoside
12～24 parts of 4～10 parts of artificial Calculus Boviss of artificial Moschus
1～8 part of 1～8 part of bufotalin of ursodesoxycholic acid
12～22 parts of Borneolum Syntheticums
2. treatment cardiovascular diseases's according to claim 1 medicine " strong heart first-aid dropping pill " is characterized in that wherein the weight proportion of each raw material is:
30～40 parts of 5～12 parts of water-soluble extract of red sage root of ginsenoside
15～22 parts of 5～8 parts of artificial Calculus Boviss of artificial Moschus
2～6 parts of 2～6 parts of bufotalins of ursodesoxycholic acid
14～20 parts of Borneolum Syntheticums
3. treatment cardiovascular diseases's according to claim 1 medicine " strong heart first-aid dropping pill " is characterized in that wherein the weight proportion of each raw material is:
40 parts of 10 parts of water-soluble extract of red sage root of ginsenoside
20 parts of 6 parts of artificial Calculus Boviss of artificial Moschus
3.3 parts of 3.3 parts of bufotalins of ursodesoxycholic acid
17.4 parts of Borneolum Syntheticums
4. according to claim 1,2 or 3 described treatment cardiovascular diseasess' medicine " strong heart first-aid dropping pill ", it is characterized in that said medicament is a said dosage form on any pharmaceutics.
5. the medicine of treatment cardiovascular disease according to claim 4 " strong heart first-aid dropping pill " is characterized in that said medicament is the drop pill or the watered pill.
6, a kind of method for preparing above-mentioned treatment cardiovascular diseases's medicine " strong heart first-aid dropping pill " is characterized in that:
(1) Stem and leaf of Radix Ginseng is extracted its total Saponin, and be dried to powder;
(2) Radix Salviae Miltiorrhizae is extracted water soluble ingredient, and be dried to powder;
(3) Venenum Bufonis is adopted silica gel column chromatography from its chloroform extracted solution, isolate cardiotonic glycoside main component bufotalin, be dried to powder;
(4) choose artificial Moschus, artificial Calculus Bovis, ursodesoxycholic acid, Borneolum Syntheticum by pharmacopeia and ministry standard;
(5) choose polyethylene glycol 6000 by national standard.
Above-mentioned effective site and effective ingredient are dissolved in specific solvent respectively in described ratio, and be no more than 1um through high pressure homogenize ultra micro emulsifying to particle diameter; Polyethylene glycol 6000 is heated to 85 ℃ to be dissolved; Then with medicine with first water solublity after fat-soluble series classification add polyethylene glycol 6000 respectively, fully stir and fuse together, the liquid storage cylinder insulation is at 85 ℃, inject then and drip the system tube, adjust vacuum negative pressure device, splash at regular time and quantity in 5～15 ℃ the coolant liquid silicone oil, under capillary effect, naturally be shrunk to ball, clean behind the airing promptly.
7. the preparation method of treatment cardiovascular diseases's according to claim 6 medicine " strong heart first-aid dropping pill ", it is characterized in that: all Chinese crude drugs and natural drug all are through the effective site of extraction separation or synthetic and effective ingredient, and assert by pharmacopeia and ministry standard, qualitative, quantitative is accurate, mature production technology, constant product quality.
8. the preparation method of treatment cardiovascular diseases's according to claim 6 medicine " strong heart first-aid dropping pill ", it is characterized in that: each effective site and effective ingredient dissolve in specific solvent: the solvent of (1) ginsenoside, water-soluble extract of red sage root is a water;
(2) solvent of artificial Moschus, artificial Calculus Bovis, ursodesoxycholic acid, bufotalin, Borneolum Syntheticum is a dehydrated alcohol.With the medicine after the above-mentioned dissolving, be no more than 1um through high pressure homogenize ultra micro emulsifying to particle diameter respectively, then, each effective ingredient is by the order of liposoluble constituent behind the first water soluble ingredient, and adding temperature respectively successively is to stir fusion in 85 ℃ of polyethylene glycol 6000s that fully melt.The ratio of medicine and carrier polyethylene glycol 6000 is 1: 9.After all finishing, inject the system tube of dripping and drip system.
9. the preparation method of treatment cardiovascular diseases's according to claim 6 medicine " strong heart first-aid dropping pill " is characterized in that: coolant liquid silicone oil liquid level is not more than 5cm with the system of dripping a water dropper distance; Cooling highly is not less than 40cm; Coolant temperature is from 15 ℃ of 5 ℃ of being reduced to the bottom gradually on top.
10. the preparation method of treatment cardiovascular diseases's according to claim 6 medicine " strong heart first-aid dropping pill " is characterized in that: dripping pill heavily is to make a tube water dropper bore diameter by dripping of different-diameter to be determined that ball heavily is not more than 100 milligrams; Drip system speed and determined, drip speed and be not more than 3 droplets/second by the negative pressure of vacuum amount in the liquid storage cylinder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001113038A CN1150915C (en) | 2000-08-25 | 2000-08-25 | Prescription of 'strong heart first-aid dropping pill' and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001113038A CN1150915C (en) | 2000-08-25 | 2000-08-25 | Prescription of 'strong heart first-aid dropping pill' and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1340344A true CN1340344A (en) | 2002-03-20 |
| CN1150915C CN1150915C (en) | 2004-05-26 |
Family
ID=4581224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001113038A Expired - Fee Related CN1150915C (en) | 2000-08-25 | 2000-08-25 | Prescription of 'strong heart first-aid dropping pill' and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150915C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107219A (en) * | 2014-07-18 | 2014-10-22 | 长春中医药大学 | Aerosol for treating coronary heart disease and angina pectoris and preparation process of aerosol |
| CN109125390A (en) * | 2018-09-29 | 2019-01-04 | 内蒙古康恩贝药业有限公司圣龙分公司 | A kind of Moschus leads to heart dripping pill and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1297288C (en) * | 2003-11-19 | 2007-01-31 | 王锦刚 | Medicine for treating cardiovascular disease, and its prepn. method |
-
2000
- 2000-08-25 CN CNB001113038A patent/CN1150915C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107219A (en) * | 2014-07-18 | 2014-10-22 | 长春中医药大学 | Aerosol for treating coronary heart disease and angina pectoris and preparation process of aerosol |
| CN104107219B (en) * | 2014-07-18 | 2018-07-27 | 长春中医药大学 | A kind of aerosol and its preparation process for treating coronary disease and angina pectoris |
| CN109125390A (en) * | 2018-09-29 | 2019-01-04 | 内蒙古康恩贝药业有限公司圣龙分公司 | A kind of Moschus leads to heart dripping pill and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150915C (en) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1247241C (en) | Liuwei Dihuang dripping pills and its preparation | |
| CN1879868A (en) | Medicine for treating dysmenorrhea and its preparing method | |
| CN101244234B (en) | Medicaments for preventing and controlling ischemia and hemorrhagic cerebrovaseular disease, and preparation thereof | |
| CN1150915C (en) | Prescription of 'strong heart first-aid dropping pill' and its preparing process | |
| CN1850167A (en) | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN1297288C (en) | Medicine for treating cardiovascular disease, and its prepn. method | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1087275A (en) | Treatment ischemic brain, cardiovascular preparation Shumaining | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN1107501C (en) | Albendazole emulsion | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN108567753A (en) | All beam dripping pill and its preparation process | |
| CN102225175B (en) | Traditional Chinese medicine dropping pill for treating headache and preparation method thereof | |
| CN103182033B (en) | One kind treats ishemic stroke Chinese medicine compound prescription preparation of active ingredient and preparation method thereof | |
| CN103656446B (en) | Treat the compound Mongolian medicinal preparation and its preparation technology of coronary heart disease | |
| CN1634509A (en) | Yitongshu drop pill for treating pain and its preparation method | |
| CN101642536B (en) | Plaster for treating hyperosteogeny | |
| CN1292738C (en) | Ginseng-pilose antler dripping pill for tonifying heart and kidney and its preparing method | |
| CN1823947A (en) | Naodesheng preparation and its new preparation method | |
| CN1650962A (en) | Chinese medicinal preparation for treating arrhythmia and its preparation method | |
| CN1362239A (en) | Nano Yixuesheng medicine for benefiting hemopoiesis and its preparation | |
| CN1425412A (en) | Compound oral thrombolytic preparation and its preparing method | |
| CN1762433A (en) | Novel medicinal formula for treating bone fracture and its preparation method | |
| CN1616054A (en) | Freeze-dried girald daphne powder injection and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA YITAI BIOLOGICAL HI-TECH CO., LTD. Free format text: FORMER OWNER: SUN MINFU Effective date: 20040827 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20040827 Address after: 017000 Erdos West Street, Erdos District, Inner Mongolia, Dongsheng Patentee after: Inner Mongolia Yitai bio Tech Co. Ltd. Address before: 264006 No. 5, Yanshan Road, Yantai Development Zone, Shandong Patentee before: Sun Minfu |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Heping Document name: Notification that Application Deemed not to be Proposed |
|
| C56 | Change in the name or address of the patentee |
Owner name: NEIMENGGU YITAI PHARMACY CO.,LTD. Free format text: FORMER NAME: INNER MONGOLIA YITAI BIOLOGICAL HI-TECH CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Inner Mongolia city Dongsheng District Tianjiao road Ordos Yitai building Patentee after: Inner Monglia Yicai Pharmaceutical Co., Ltd. Address before: Erdos West Street, Erdos District, Erdos City, Inner Mongolia, Dongsheng Patentee before: Inner Mongolia Yitai bio Tech Co. Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: INNER MONGOLIA KANG'ENBEI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: INNER MONGLIA YICAI PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Hangjinqi town the Inner Mongolia Autonomous Region City State Road 109 North 017400 Erdos Patentee after: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Address before: 017000 Erdos the Inner Mongolia Autonomous Region District of Dongsheng City Road Tianjiao Yitai building Patentee before: Inner Monglia Yicai Pharmaceutical Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENGLONG BRANCH OF INNER MONGOLIA KANG'EN PHARMAC Free format text: FORMER OWNER: INNER MONGOLIA KANG'ENBEI PHARMACEUTICAL CO., LTD. Effective date: 20150821 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150821 Address after: Hangjinqi town 017400 the Inner Mongolia Autonomous Region City 109 State Road, North Road, Erdos SINJ East Patentee after: Inner Mongolia Conba Pharmaceutical Co. Ltd. Shenglong branch Address before: Hangjinqi town the Inner Mongolia Autonomous Region City State Road 109 North 017400 Erdos Patentee before: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170405 Address after: 017400 Inner Mongolia city Erdos Hangjinqi Seney town 109 State Road, North Road East Patentee after: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Address before: Hangjinqi town 017400 the Inner Mongolia Autonomous Region City 109 State Road, North Road, Erdos SINJ East Patentee before: Inner Mongolia Conba Pharmaceutical Co. Ltd. Shenglong branch |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040526 Termination date: 20190825 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |